

Special and Vulnerable Populations COVID-19 Forum

November 18, 2022

A dark blue diagonal graphic that starts from the bottom left corner and extends towards the top right corner, covering the lower half of the page.

Zoom Etiquette

- All participants muted upon entry, please raise hand if you would like to unmute
- Cameras on (if possible)
- Use the chat box to introduce yourself or ask/answer questions



National Training and Technical Assistance Partners (NTTAPs)



Today's Facilitators



Matt Beierschmitt, MPP (he/him)
Senior Program Manager
National Nurse-led Care Consortium



Gladys Carrillo, LCSW (she/her/ella)
Director of Program Services
National Center for Farmworker Health

Today's Agenda

- Welcome and Introductions
- COVID-19 Resource Updates
- HRSA: Direct Allocation Supply
 - **Larry Byrd**
 - **Felicia Sanchez**
- ASPR: Oral Antiviral Access
 - **Dr. Meghan Pennini, PhD**
- CDC: Flu, RSV & COVID
 - **Dr. Tim Uyeki, MD, MPH, MPP**
 - **La'Shawnda Mansfield**
- Conclusion and Evaluation

Special and Vulnerable Populations COVID-19 Forum

HRSA Updates and special topics based on status of COVID-19 & Health Center challenges

Session 1: September 24, 2021 - Introductions

Session 2: November 19, 2021 - Vaccine Confidence Strategy

Session 3: January 28, 2022 - Workforce Wellness and Resilience

Session 4: March 25, 2022 - Impact of COVID-19 on Patient Mental and Behavioral Health

Session 5: May 20, 2022 - Breakout Discussions on Forum Topics

Session 6: July 22, 2022- Therapeutics and Equity; COVID-19 Subvariants; Childhood vaccination

Session 7: September 23, 2022 - COVID-19 Bivalent Boosters; Monkeypox

Session 8: November 18, 2022 - Incorporating COVID-19 Clinical Care within Clinic Workflows (COVID-19 Program Update, Access to Oral Therapeutics, Flu, RSV)

Session 9: January 27, 2023 - TBD—Participants/Audience offer suggestions in the Evaluation!!!

HRSA COVID-19 FAQs

COVID-19 Frequently Asked Questions (FAQs)

If the answer to your question is not located here or in the [Coronavirus-Related Funding FAQs](#), please submit it through [Health Center Program Support online](#) and select "Coronavirus Inquiries (COVID-19)" as the issue type, or call 877-464-4772, option 2, 7:00 a.m. to 8:00 p.m. ET, Monday-Friday (except federal holidays).

Access more [COVID-19 Information for Health Centers and Partners](#).

Access [FY 2020 Health Center Program Look-Alikes: Expanding Capacity for Coronavirus Testing \(LAL ECT\) Frequently Asked Questions](#).

Access resources for [UDS Novel Coronavirus Disease \(COVID-19\) Reporting](#).

https://bphc.hrsa.gov/emergency-response/coronavirus-frequently-asked-questions?field_faq_category_tid=306&combine=

Health Center Resource Clearinghouse: Materials section of Tests, Masks, and Therapeutics Page



ABOUT ▾ PARTNERS ▾ SEARCH ▾ LEARNING ▾ PRIORITY TOPICS ▾ PROMISING PRACTICES ▾ CONNECT ▾

New Resources: Monkeypox Information (Fact Sheet, Infographics, Webinar) | Affordable Connectivity Program Consumer Outreach Toolkit

 Search the Clearinghouse: Enter Search Terms Here

SEARCH

HOME TEST KITS, MASKS, AND THERAPEUTICS

This page aggregates the most recent federal information on home test kits and masks provided to health centers and provides a mechanism to submit resources, templates, and sample documents.

As part of the [HRSA COVID-19 Testing Supply Program](#), HRSA-funded health centers, Health Center Program look-alikes, and Medicare-certified Rural Health Clinics are invited to order free, FDA-authorized COVID-19 at-home self-test kits for distribution at no cost to patients and communities, especially populations at greatest risk from adverse outcomes related to COVID-19.



COVID-19

COVID-19 Home Test Kits, Masks,
and Therapeutics

Vaccine Distribution

Submit a TTA Resource

<https://www.healthcenterinfo.org/priority-topics/covid-19/home-test-kits-resources-and-call-for-materials/>

Got Promising Practices or Tools?

If you have **promising practices, sample staff recruitment tools or template documents**, please consider sharing on the [Health Center Resource Clearinghouse Vaccine Distribution](#) page by completing this short [submit your resource](#) form.



[ABOUT](#) ▾ [PARTNERS](#) ▾ [SEARCH](#) ▾ [LEARNING](#) ▾ [PRIORITY TOPICS](#) ▾ [PROMISING PRACTICES](#) ▾ [CONNECT](#) ▾

New Resources: Monkeypox Information (Fact Sheet, Infographics, Webinar) | Affordable Connectivity Program Consumer Outreach Toolkit

 **Search the Clearinghouse:** Enter Search Terms Here

SEARCH

HRSA/BPHC Update

Direct Allocation Supply

HHS/ASPR Update

Oral Antiviral Access



Larry Byrd, MHA

Lead Public Health Analyst
Center of Health Center Innovation,
OQI/BPHC



Felicia Sanchez, MS

Statistician
Center of Health Center Innovation,
OQI/BPHC



Dr. Meghan Pennini, PhD

Chief Therapeutics Officer
HHS Coordination Operations &
Response Element, ASPR



Special and Vulnerable Populations COVID-19 Forum

Friday, November 18, 2022

Health Center COVID-19 Response Programs Team
Bureau of Primary Health Care (BPHC)
Health Resource and Services Administration (HRSA)

Vision: Healthy Communities, Healthy People



Health Center COVID-19 Response Programs

AGEND

HRSA

- COVID-19 Program Updates and Takeaways
- Outreach and Partnerships Through the Pandemic
- COVID-19 Resources
- Resources for the Prevention and Mitigation of Monkeypox Cases

Administration for Strategic Preparedness and Response (ASPR)

- COVID-19 Therapeutic Oral Antiviral Access and Commercialization



COVID-19 Program Updates and Takeaways

Vaccine

At-Home
Tests

Continual health education on the importance of bivalent booster

Single-dose vials will be helpful to reduce potential wastage

Point-of-Care
Tests

N-95 Masks


Social media and print health promotion resources remain in demand

Anti-Viral
Therapeutics


COVID-19 prevention and treatment → routine part of primary care




Outreach and Partnerships Through the Pandemic



Equitable access to COVID-19 supplies for special populations



Building COVID-19 vaccine confidence



Community health worker model to support COVID-19 vaccination

COVID-19 Resources – Where to Find Vaccines & Supplies

Vaccine Program

- Finding COVID-19 Vaccines
- ✓ [Vaccines.gov](https://www.vaccines.gov)
- ✓ [State Health Department](#)
- ✓ [Individuals Who Are Homebound](#)

Testing Supply Program

- Finding COVID-19 Testing Supplies
- ✓ [Find a Health Center](#)

Therapeutics Program

- Finding COVID-19 Therapeutics
- ✓ [Test to Treat Locator](#)
- ✓ [Therapeutic Locator for Providers](#)

In the chat... Does your health center have an adequate supply of COVID-19 vaccines, therapeutics, and testing supplies to support your community needs through the holidays and winter months?



Additional COVID-19 Resources

Pfizer Bivalent COVID-19 Booster

- [Pfizer Bivalent Booster Fact Sheet EUA | FDA](#)

Moderna Bivalent COVID-19 Vaccine Booster

- [Moderna Bivalent Booster Fact Sheet EUA | FDA](#)

Novavax COVID-19 Vaccine

- [Booster for Adults and a Two-Dose Primary Series for Adolescents Aged 12 through 17](#)

Vaccine Coadministration

- [Summary Document for Interim Clinical Considerations](#)



In the chat... What are the top concerns of your Health Center regarding the commercialization of COVID-19 therapeutics and vaccines?



Resources for the Prevention and Mitigation of Monkeypox Cases

- As of November 16: 28,999 confirmed cases in the United States
- Ensuring sufficient resources and outreach strategies are critical for people experiencing homelessness
 - CDC’s Morbidity and Mortality Weekly Report (MMWR) recently released “[Severe Monkeypox in Hospitalized Patients](#)”, which showed that 23% of cases in the study experienced homelessness
 - [Toolkit](#) for people experiencing homelessness
 - CDC’s Monkeypox Response Clinical Escalations Team is available 24 hours a day, 7 days a week, by email at eocevent482@cdc.gov, or by phone at 770-488-7100





COVID-19 Therapeutics Update

Meghan Pennini, PhD

Chief Therapeutics Officer

HHS Coordination Operations and Response Element (H-CORE)/ASPR

November 18, 2022

<https://aspr.hhs.gov/COVID-19/Therapeutics/Pages/default.aspx>

In the chat...

Are you currently dispensing oral antivirals?

If no, what are your concerns/constraints that are preventing this?


If yes, what information do you need to successfully maintain dispensing capabilities as we transition to commercialization?

COVID-19 Therapeutics

- Federal government continues to provide therapeutics to state and territorial health departments, pharmacy partners, and federal entities for free.
- Patient counseling and appropriate prescribing by healthcare providers are critical in our efforts to prevent further morbidity and mortality from COVID-19.
- Equity and access are key.
- Oral antivirals are available at >45,000 locations nationwide.



Summary of COVID-19 Preventative Agents & Outpatient Treatments



COVID-19 Vaccines

Monoclonal Antibodies for PrEP

- Evusheld (tixagevimab + cilgavimab, AZ)

None currently authorized for use in any US state or territory.

Oral Antivirals

- Paxlovid (nirmatrelvir + ritonavir, Pfizer)
- Lagevrio (molnupiravir, Merck) – Alternative

Monoclonal Antibodies

- Bebtelovimab (Lilly) – Alternative

IV Antiviral

- Veklury® (remdesivir, Gilead)

Please see [NIH Current Inpatient Therapies](https://www.covid19treatmentguidelines.nih.gov/therapies/) (https://www.covid19treatmentguidelines.nih.gov/therapies/)

There is currently **ample supply** of all authorized and approved therapeutics – every eligible patient should have access to these medications

.....→
[Therapeutic Management of Nonhospitalized Adults With COVID-19](#)
[Therapeutic Management of Hospitalized Adults With COVID-19](#)

- HHS distribution
- Commercially available

*refer to individual product Fact Sheets for authorization details

COVID-19 Treatments and Medications


Treatment	Who	When	How
<u>Nirmatrelvir with Ritonavir (Paxlovid)</u> <i>Antiviral</i>	Adults; children ages 12 years and older	Start as soon as possible; must begin within 5 days of when symptoms start	Taken at home by mouth (orally)
<u>Remdesivir (Veklury)</u> <i>Antiviral</i>	Adults and children	Start as soon as possible; must begin within 7 days of when symptoms start	Intravenous (IV) infusions at a healthcare facility for 3 consecutive days
<u>Molnupiravir (Lagevrio)</u> <i>Antiviral</i>	Adults	Start as soon as possible; must begin within 5 days of when symptoms start	Taken at home by mouth (orally)
<u>Bebtelovimab</u> <i>Monoclonal antibody</i>	Adults; children ages 12 years and older	Start as soon as possible; must begin within 7 days of when symptoms start	Single IV injection

<https://www.cdc.gov/coronavirus/2019-ncov/your-health/treatments-for-severe-illness.html>

COVID-19 Treatments and Medications


What you need to know:

- If you test positive for COVID-19 and are more likely to get very sick, treatments are available that can reduce your chances of hospitalization and death
- Don't delay! Treatment must be started within days after you first develop symptoms to be effective
- The HHS [COVID-19 Treatments Locator](#) can help you find a location that offers testing and treatment or a pharmacy where you can fill a prescription



Get tested for COVID-19 early if you feel sick.
Get treated quickly if you test positive.

Use the Test to Treat Locator to help you get started.

 **ASPR**
ADDITIONAL SUPPORT PROGRAM
www.aspr.hhs.gov

Test to Treat
The Sooner The Better

<https://www.cdc.gov/coronavirus/2019-ncov/your-health/treatments-for-severe-illness.html>

Test to Treat: About the Program

- Overall goal of Test to Treat program is to increase access to COVID-19 oral therapeutics, **particularly for individuals who don't have ready access to a health care provider**
- COVID-19 treatments delivered as part of Test to Treat Program (Paxlovid and Lagevrio) must be taken within 5 days of initial COVID-19 symptoms.
 - Helps close gap between positive COVID-19 test and receiving treatment for those eligible
- Builds upon existing distribution of oral antivirals we are already making available at no cost to thousands of locations nationwide.
- More than 2500 Test to Treat sites across country; more than 45,000 total locations with oral antivirals
- An individual's healthcare providers remain the first option for care; Test to Treat sites are one additional access point.

DON'T DELAY: TEST SOON AND TREAT EARLY

| COVID-19 |

If you are at high risk of getting very sick from COVID-19, and test positive, treatment may be available.



Get tested as soon as possible after your symptoms start.

Contact your healthcare provider right away if your result is positive.




Don't delay. Treatment must be started early to work.



cdc.gov/coronavirus

Test to Treat Locator

- Test to Treat site locator launched on 3/30.
- Identifies all Test to Treat program sites and all sites to fill an existing prescription.
 - Telehealth options are also visible on locator tool
- Call center also available:
[1-800-232-0233](tel:1-800-232-0233) (TTY [1-888-720-7489](tel:1-888-720-7489)) to get help in English, Spanish, and more than 150 other languages—8 AM to 12 midnight ET, 7 days a week.
- [Disability Information and Access Line \(DIAL\)](#) also available to specifically help those with disabilities access services. [1-888-677-1199](tel:1-888-677-1199), Monday to Friday from 9 AM to 8 PM ET or email DIAL@usaginganddisability.org



<https://covid-19-test-to-treat-locator-dhhs.hub.arcgis.com/>

Related Resources

Helpful Information and Resources

- HHS Therapeutics Homepage
- [Product Expiration Date Extensions](#)
- Test to Treat Initiative webpage and Fact Sheet
- [Test to Treat Site Locator](#) and [Digital Tool Kit](#)
- [General Therapeutics Locator](#)
- [HHS Clinical Implementation Guide](#)
- [Outpatient Therapeutics Decision Aid](#)
- [Side-by-Side Overview of Outpatient Therapeutics](#)
- [ASPR Regional Emergency Coordinators](#)
- [CMS reimbursement information for mAbs](#)
- [CMS reimbursement information for oral antivirals](#)

Latest COVID-19 Therapeutics Updates Found at aspr.hhs.gov

Questions?



Thank You!

Bureau of Primary Health Care (BPHC)

Health Resources and Services Administration (HRSA)



For general information on the Health Center COVID-19 Vaccine Program, please visit [HRSA.gov](https://www.hrsa.gov).

bphc.hrsa.gov

[BPHC Contact Form](#)



[Sign up for the *Primary Health Care Digest*](#)



*Guest Speakers
from CDC*

Flu,

COVID and RSV



Tim Uyeki, MD, MPH, MPP
Chief Medical Officer,
CDC Influenza Division, Office of the
Director




La'Shawnda Mansfield, MPH
Public Health Analyst




Influenza Activity Update, Week 45

Tim Uyeki, MD, MPH, MPP
Influenza Division, CDC


Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, May 22, 2022 – November 12, 2022



Influenza Positive Tests Reported to CDC by U.S. Public Health Laboratories, National Summary, May 22, 2022 – November 12, 2022




Percentage of Outpatient Visits for Respiratory Illness Reported By The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), Weekly National Summary, 2022-2023* and Selected Previous Seasons




This system monitors visits for ILI (fever and cough or sore throat), not laboratory confirmed influenza and may capture patient visits due to other respiratory pathogens that cause similar symptoms.

Percentage of Outpatient Visits for Respiratory Illness by Age Group
Reported by the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet),
Weekly National Summary, May 22, 2022–November 12, 2022*




Cumulative Rate of Laboratory-Confirmed Influenza Hospitalizations among cases of all ages, 2015-16 to 2022-23, MMWR Week 45



**In this figure, cumulative rates for all seasons prior to the 2022-23 season reflect end-of-season rates. For the 2022-23 season, rates for recent hospital admissions are subject to reporting delays. As hospitalization data are received each week, prior case counts and rates are updated accordingly.

Pneumonia, Influenza, and COVID-19 Mortality from the National Center for Health Statistics Mortality Surveillance System

Data as of November 17, 2022





2022-2023 Flu Vaccine Campaigns

November 18, 2022


Current Environment

- Overall decline in flu vaccinations
 - Significant drops in flu vaccination coverage among children and pregnant women
 - Significant disparities in vaccination rates across racial demographics
- New preferential recommendation for people 65 and older
- Relatively low flu activity for two consecutive seasons
- Flu vaccine effectiveness during “well matched seasons” ranges from 40% to 60% (35% last season)
- Flu activity arrived early, is on-going and elevated nationally, hospitalization rates are high for this time of year.

2022-2023 Flu Vaccine Campaign:

- Strong emphasis on health equity across communications
- Two major campaigns (materials available in English/Spanish)
 - CDC campaign
 - Primary Audience: Children/Parents
 - Sub-Audiences: People with chronic conditions, people 65 and older, pregnant people
 - Ad Council Collaboration Primary audience: General public with an emphasis on Black and Hispanic audiences 18-64 years ambivalent about flu vaccine

2022-2023 Flu Vaccine Campaign:





HELP THEM FIGHT FLU
SO THEY CAN DO WHAT THEY DO.

TALK TO THEIR DOCTOR ABOUT GETTING THEM A FLU VACCINE.

#FIGHTFLU



HELP THEM FIGHT FLU
SO THEY CAN DO WHAT THEY DO.

TALK TO THEIR DOCTOR ABOUT GETTING THEM A FLU VACCINE.

#FIGHTFLU



Help Them Fight Flu




Fight Flu – Don't Let it Stop You | CDC

Ad Council/AMA/CDC Collaborative Campaign

- Encourage vaccination through earned and **donated media** (print, television, radio, social media, out-of-home and digital channels)
- Campaign:
 - “No Time for Flu”
 - Flu FOMO
 - Micro-influencer outreach
 - **New: Doctor’s Orders**

No Time for Flu



Flu FOMO



Advertising agency fluent360 created the campaign's ad pro bono.

<https://getmyflushot.adcouncilkit.org/psas/>

LEVERAGING NIVW TO REACH CORE AUDIENCES

This year's National Influenza Vaccination Week (NIVW) (**December 5-9**) has a goal of **focusing public attention on the importance of flu vaccination through earned and owned activations, with opportunities to engage key partners.**



Earned Media

- Bylined article (*tentative*)
- Proactive, targeted outreach to key publications*



Partner Activations

- "Flu-etting" social activation on Instagram Reels in collaboration with key partners*
- Refreshed NIVW landing page and partner toolkit




Social Media

- Microinfluencer engagement
- Organic social content and graphics on CDC flagship handles (Twitter, Facebook, and Instagram)*

Activations will reach both our core campaign audience of **parents of children 6 months to 12 years old** and secondary audiences, which include **adults with chronic conditions, pregnant people, and adults 65 and older.**

*Denotes activities that will account for both core campaign and secondary audience(s)


DRIVING CONVERSATION ON OWNED CHANNELS



Examples of DRAFT Content for CDC Organic Channels – Still in Development; Not Fully Approved

National Influenza Vaccination Week | CDC

LEVERAGING PARTNER NETWORKS



Twitter, Facebook, Instagram and LinkedIn Content



Posters and Flyers



Frames for Twitter, Facebook and Instagram

Examples of DRAFT Partner Content – Still in Development; Not Yet Approved

Other partner content will include Instagram Story templates, a sample newsletter blurb, patient reminder messages, and a template matte release, all available in the **2022 NIVW Digital Toolkit**.

Communication Resources

- General Resources: [Seasonal Flu Partner Resources Center | CDC](#)
- Parents: [Parents: Help Children Fight Flu | CDC](#)
- Higher risk groups: [People at Higher Risk of Flu Complications | CDC](#)
- CDC Campaign Social media toolkit: [Social Media Toolkit | CDC](#)
- Ad Council Campaign materials: [GetMyFluShot.org](#)
- Prevention Education: [Prevent Seasonal Flu | CDC](#)
- Symptoms and Testing: [Flu Symptoms & Diagnosis | CDC](#)
- Treatment: [Flu Treatment | CDC](#)
- For Health Care Providers: [Information for Health Professionals | CDC](#)

Questions for Guest Speakers?



EVALUATION

Please take the time to complete the Forum evaluation via Zoom, and help us improve this activity for future sessions.

Give your input for our next session in January.

Thank you!

See you next year!

January 27, 2023